Ahmed Ali, Young James B, Love Thomas E, Levesque Raynald, Pitt Betram
University of Alabama at Birmingham, and Veterans Affairs Medical Center, Birmingham, 1530 3rd Avenue South, CH19-219, Birmingham, Alabama 35294-2041, USA.
Int J Cardiol. 2008 Apr 10;125(2):246-53. doi: 10.1016/j.ijcard.2007.05.032. Epub 2007 Aug 16.
Non-potassium-sparing diuretics may increase mortality and hospitalizations in heart failure patients. Most heart failure patients are older adults, yet the effect of diuretics on cause-specific mortality and hospitalizations in older adults with heart failure is unknown. The objective of this propensity-matched study was to determine the effect of diuretics on mortality and hospitalizations in heart failure patients >or=65 years.
Of the 7788 Digitalis Investigation Group participants, 4036 were >or=65 years and 3271 (81%) were receiving diuretics. Propensity scores for diuretic use for each of the 4036 patients were calculated using a non-parsimonious multivariable logistic regression model incorporating all measured baseline covariates, and were used to match 651 (85%) patients not receiving diuretics with 651 patients receiving diuretics. Effects of diuretics on mortality and hospitalization at 37 months of median follow-up were assessed using matched Cox regression models.
All-cause mortality occurred in 173 patients not receiving diuretics and 208 patients receiving diuretics respectively during 2056 and 1943 person-years of follow-up (hazard ratio {HR}=1.36; 95% confidence interval {CI}=1.08-1.71; p=0.009). All-cause hospitalizations occurred in 413 patients not receiving and 438 patients receiving diuretics respectively during 1255 and 1144 person-years of follow-up (HR=1.18; 95% CI=0.99-1.39; p=0.063). Diuretic use was associated with significant increased risk of cardiovascular mortality (HR=1.50; 95% CI=1.15-1.96; p=0.003).and heart failure hospitalization (HR=1.48; 95% CI=1.13-1.94; p=0.005).
Chronic diuretic use was associated with significant increased mortality and hospitalization in ambulatory older adults with heart failure receiving angiotensin converting enzyme inhibitor and diuretics.
非保钾利尿剂可能会增加心力衰竭患者的死亡率和住院率。大多数心力衰竭患者为老年人,但利尿剂对老年心力衰竭患者特定病因死亡率和住院率的影响尚不清楚。这项倾向匹配研究的目的是确定利尿剂对65岁及以上心力衰竭患者死亡率和住院率的影响。
在7788名洋地黄研究组参与者中,4036人年龄在65岁及以上,3271人(81%)正在使用利尿剂。使用包含所有测量的基线协变量的非简约多变量逻辑回归模型,计算4036名患者中每一位使用利尿剂的倾向得分,并用于将651名(85%)未使用利尿剂的患者与651名使用利尿剂的患者进行匹配。使用匹配的Cox回归模型评估利尿剂在中位随访37个月时对死亡率和住院率的影响。
在2056和1943人年的随访期间,未使用利尿剂的173名患者和使用利尿剂的208名患者分别发生全因死亡(风险比{HR}=1.36;95%置信区间{CI}=1.08 - 1.71;p = 0.009)。在1255和1144人年的随访期间,未使用利尿剂的413名患者和使用利尿剂的438名患者分别发生全因住院(HR = 1.18;95% CI = 0.99 - 1.39;p = 0.063)。使用利尿剂与心血管死亡率显著增加风险相关(HR = 1.50;95% CI = 1.15 - 1.96;p = 0.003),以及心力衰竭住院率相关(HR = 1.48;95% CI = 1.13 - 1.94;p = 0.005)。
在接受血管紧张素转换酶抑制剂和利尿剂治疗的门诊老年心力衰竭患者中,长期使用利尿剂与死亡率和住院率显著增加相关。